Yang Shuangshuang, Shen Shan, Hou Ning
Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Graduate Department, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, China.
Front Pharmacol. 2022 Jun 21;13:858693. doi: 10.3389/fphar.2022.858693. eCollection 2022.
Coronavirus disease 2019 was first discovered in December 2019 and subsequently became a global pandemic with serious political, economic, and social implications worldwide. We urgently need to find drugs that can be effective against COVID-19. Among the many observational studies, ivermectin has attracted the attention of many countries. Ivermectin is a broad-spectrum antiparasitic drug that also has some antiviral effects. We reviewed studies related to ivermectin for the treatment of COVID-19 over the last 2 years (2019.12-2022.03) search engines such as PubMed, Web of Science, and EBSCOhost. Seven studies showed a lower mortality rate in the ivermectin group than in the control group, six studies found that the ivermectin group had a significantly fewer length of hospitalization than the control group, and eight studies showed better negative RT-PCR responses in the IVM group than in the control group. Our systematic review indicated that ivermectin may be effective for mildly to moderately ill patients. There is no clear evidence or guidelines to recommend ivermectin as a therapeutic agent for COVID-19, so physicians should use it with caution in the absence of better alternatives in the clinical setting, and self-medication is not recommended for patients.
2019冠状病毒病于2019年12月首次被发现,随后成为一场全球大流行,在全球范围内产生了严重的政治、经济和社会影响。我们迫切需要找到能够有效对抗COVID-19的药物。在众多观察性研究中,伊维菌素引起了许多国家的关注。伊维菌素是一种广谱抗寄生虫药物,也具有一些抗病毒作用。我们通过PubMed、Web of Science和EBSCOhost等搜索引擎,回顾了过去两年(2019年12月至2022年3月)与伊维菌素治疗COVID-19相关的研究。七项研究表明,伊维菌素组的死亡率低于对照组,六项研究发现,伊维菌素组的住院时间明显短于对照组,八项研究表明,伊维菌素组的RT-PCR阴性反应优于对照组。我们的系统评价表明,伊维菌素可能对轻至中度患者有效。目前尚无明确证据或指南推荐伊维菌素作为COVID-19的治疗药物,因此医生在临床环境中没有更好的替代方案时应谨慎使用,不建议患者自行用药。